欧盟临床申请公告出来_老虎社区_美港股上老虎 - 老虎社区

欧盟临床申请公告出来之后，走势就稳住了。不用天天涨，这种有催化的时候能走独立行情就行$瑞博生物-B(06938)$

@独立投资者吴强：瑞博生物向欧盟递交靶向INHBE的siRNA药物RBD3133 I期临床试验申请

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":616107772572376,"tweetId":"616107772572376","gmtCreate":1791436138428,"gmtModify":1791436140479,"author":{"id":4238290210542282,"idStr":"4238290210542282","authorId":4238290210542282,"authorIdStr":"4238290210542282","name":"摩尔視野","avatar":"https://static.tigerbbs.com/efa46d03b9bc8f6cecec0404bd519402","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>欧盟临床申请公告出来之后，走势就稳住了。不用天天涨，这种有催化的时候能走独立行情就行<a target=\"_blank\" href=\"https://laohu8.com/S/06938\">$瑞博生物-B(06938)$ </a>\n<br></body></html>","htmlText":"<html><head></head><body>欧盟临床申请公告出来之后，走势就稳住了。不用天天涨，这种有催化的时候能走独立行情就行<a target=\"_blank\" href=\"https://laohu8.com/S/06938\">$瑞博生物-B(06938)$ </a>\n<br></body></html>","text":"欧盟临床申请公告出来之后，走势就稳住了。不用天天涨，这种有催化的时候能走独立行情就行$瑞博生物-B(06938)$","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/616107772572376","repostId":616118803419280,"repostType":1,"repost":{"magic":2,"id":616118803419280,"tweetId":"616118803419280","gmtCreate":1791427168112,"gmtModify":1791427174620,"author":{"id":4132110803756740,"idStr":"4132110803756740","authorId":4132110803756740,"authorIdStr":"4132110803756740","name":"独立投资者吴强","avatar":"https://static.tigerbbs.com/11bc8fea6bad079018ffc772d0d8db48","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.09.16","individualDisplayEnabled":1,"backgroundColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.09.25","individualDisplayEnabled":1,"backgroundColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}}],"wearingBadges":[{"categoryType":2007,"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","isScarce":1,"plateColors":{"bgColor":{"dark":"#2f2a1f","tint":"#fcf6e5"},"fontColor":{"dark":"#dea95e","tint":"#885600"}},"effectEnabled":0,"redirectLinkEnabled":1,"redirectLinkType":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","redirectLinkValidityFrom":1680048000000,"redirectLinkValidityTo":1996358400000,"validityToTimestamp":1792902001277,"sortingWeight":0,"wearable":1}],"fanSize":42,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"瑞博生物向欧盟递交靶向INHBE的siRNA药物RBD3133 I期临床试验申请","html":"<html><head></head><body><p><strong>2026年10月8日，中国苏州、瑞典默恩达尔</strong></p>\n<p>苏州瑞博生物技术股份有限公司(06938.HK)及其子公司Ribocure Pharmaceuticals AB(以下合称“瑞博生物”)宣布，已在欧盟成功提交自研小核酸药物RBD3133的I期临床试验申请(CTA)。RBD3133是一款靶向INHBE(抑制素β亚基E)的创新siRNA候选药物，拟开发适应症为超重和肥胖。</p>\n<p>肥胖已成为全球最重大的公共卫生挑战之一，影响超10亿人口，显著加重2型糖尿病、心血管疾病以及其他肥胖相关合并症的疾病负担。尽管肥胖治疗领域在近年已取得诸多进展，但临床上仍亟需能够直击代谢功能障碍底层生物学机制、带来持久临床获益的创新疗法。</p>\n<p>RBD3133旨在选择性沉默INHBE基因，该基因负责编码激活素E(activin E)蛋白。人类遗传学研究证实：携带INHBE天然功能丧失突变的人群，拥有更健康的脂肪分布、更优的代谢表型，其冠心病与2型糖尿病预估发病风险更低。上述研究发现印证，INHBE是肥胖及相关代谢疾病极具潜力的治疗靶点。</p>\n<p>本次I期临床试验为一项随机、安慰剂对照研究，旨在评估皮下注射RBD3133在超重或肥胖受试者中的安全性、耐受性、药代动力学与药效学特征。该试验是RBD3133的首次人体试验，将为候选药物后续临床开发奠定核心基础。</p>\n<p>RBD3133是瑞博生物心血管代谢疾病领域的小核酸药物开发矩阵布局的重要一环，将成为减肥相关心血管和代谢疾病治疗的基石药物。作为瑞博生物减肥领域的第一个候选药物，RBD3133也再次体现了公司战略方向：面向存在巨大未满足临床需求的大规模患者群体，开发创新治疗药物。</p>\n<p><a href=\"https://laohu8.com/S/06938\">$瑞博生物-B(06938)$</a></p></body></html>","htmlText":"<html><head></head><body><p><strong>2026年10月8日，中国苏州、瑞典默恩达尔</strong></p>\n<p>苏州瑞博生物技术股份有限公司(06938.HK)及其子公司Ribocure Pharmaceuticals AB(以下合称“瑞博生物”)宣布，已在欧盟成功提交自研小核酸药物RBD3133的I期临床试验申请(CTA)。RBD3133是一款靶向INHBE(抑制素β亚基E)的创新siRNA候选药物，拟开发适应症为超重和肥胖。</p>\n<p>肥胖已成为全球最重大的公共卫生挑战之一，影响超10亿人口，显著加重2型糖尿病、心血管疾病以及其他肥胖相关合并症的疾病负担。尽管肥胖治疗领域在近年已取得诸多进展，但临床上仍亟需能够直击代谢功能障碍底层生物学机制、带来持久临床获益的创新疗法。</p>\n<p>RBD3133旨在选择性沉默INHBE基因，该基因负责编码激活素E(activin E)蛋白。人类遗传学研究证实：携带INHBE天然功能丧失突变的人群，拥有更健康的脂肪分布、更优的代谢表型，其冠心病与2型糖尿病预估发病风险更低。上述研究发现印证，INHBE是肥胖及相关代谢疾病极具潜力的治疗靶点。</p>\n<p>本次I期临床试验为一项随机、安慰剂对照研究，旨在评估皮下注射RBD3133在超重或肥胖受试者中的安全性、耐受性、药代动力学与药效学特征。该试验是RBD3133的首次人体试验，将为候选药物后续临床开发奠定核心基础。</p>\n<p>RBD3133是瑞博生物心血管代谢疾病领域的小核酸药物开发矩阵布局的重要一环，将成为减肥相关心血管和代谢疾病治疗的基石药物。作为瑞博生物减肥领域的第一个候选药物，RBD3133也再次体现了公司战略方向：面向存在巨大未满足临床需求的大规模患者群体，开发创新治疗药物。</p>\n<p><a href=\"https://laohu8.com/S/06938\">$瑞博生物-B(06938)$</a></p></body></html>","text":"2026年10月8日，中国苏州、瑞典默恩达尔 苏州瑞博生物技术股份有限公司(06938.HK)及其子公司Ribocure Pharmaceuticals AB(以下合称“瑞博生物”)宣布，已在欧盟成功提交自研小核酸药物RBD3133的I期临床试验申请(CTA)。RBD3133是一款靶向INHBE(抑制素β亚基E)的创新siRNA候选药物，拟开发适应症为超重和肥胖。 肥胖已成为全球最重大的公共卫生挑战之一，影响超10亿人口，显著加重2型糖尿病、心血管疾病以及其他肥胖相关合并症的疾病负担。尽管肥胖治疗领域在近年已取得诸多进展，但临床上仍亟需能够直击代谢功能障碍底层生物学机制、带来持久临床获益的创新疗法。 RBD3133旨在选择性沉默INHBE基因，该基因负责编码激活素E(activin E)蛋白。人类遗传学研究证实：携带INHBE天然功能丧失突变的人群，拥有更健康的脂肪分布、更优的代谢表型，其冠心病与2型糖尿病预估发病风险更低。上述研究发现印证，INHBE是肥胖及相关代谢疾病极具潜力的治疗靶点。 本次I期临床试验为一项随机、安慰剂对照研究，旨在评估皮下注射RBD3133在超重或肥胖受试者中的安全性、耐受性、药代动力学与药效学特征。该试验是RBD3133的首次人体试验，将为候选药物后续临床开发奠定核心基础。 RBD3133是瑞博生物心血管代谢疾病领域的小核酸药物开发矩阵布局的重要一环，将成为减肥相关心血管和代谢疾病治疗的基石药物。作为瑞博生物减肥领域的第一个候选药物，RBD3133也再次体现了公司战略方向：面向存在巨大未满足临床需求的大规模患者群体，开发创新治疗药物。 $瑞博生物-B(06938)$","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/616118803419280","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["06938"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1206,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":320,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["06938"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":100,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/616107772572376"}